Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran

Table 5 Immunogenicity and seroconversion rates to measles and rubella components of MMR vaccine currently used in Iran

Author/province vaccine brand	Years of study	No of Subjects	Age	Lab method	Responses Rate MMR (%)
					MMR1^{first dose}		MMR2^{2second dose}
					M	R	M	R
Saffar, Mazandaran Razi-Iran [48]	2007	112	12.10 mo	ELISA	84.8%	53%	–	–
Saffar, Mazandaran Razi-Iran [49]	2011	249 228	18 m 6 yr	ELISA	74% 6- mo after MMR1 5- yr after MMR1 78.9%	75%6- mo afetr MMR1 66% 5- year after MMR1	94.4%	92.6%
							1- mo after MMR2
							98.2	87%
							1- mo after MMR2
Shamsizadeh, Ahwaz Karaj-Iran Razi Iran [50]	2010–2011	70 90	18 mo 6.5 yr ^a	ELISA	6- mo after MMR1 42.9% -	6- mo after MMR190% -	- 45.6%	- 87.8%^a
Tabatabaei, Razi-Iran [51]	2011–2012	240	13.27 mo [12,13,14,15]	ELISA	75.8%	73.8%	–	–
Zahrari, Baluchestan –Kerman-Hormozgan Razi-Iran [36]	2016	236	> 12 mo	ELISA	91.2%^b		–
Izadi, Baluchestan –Kerman-Hormozgan Razi-Iran [37]	2015	663	30–54 mo		–	–	94.6%^c	–

^a: One dose of MMR vaccine in addition to two doses of MV at the ages nine and 15 months.
^b: Based on strict control of the vaccination administration technique and cold chain control by the researchers.
^c: Two- doses of MMR at the ages of 12 and 18 months.

ISSN: 1471-2334